Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SEC Calls For Final Changes as Potential ETF Approval Looms

SEC Calls For Final Changes as Potential ETF Approval Looms

DailyCoinDailyCoin2023/12/26 02:01
By:DailyCoin
  • The SEC is taking one final look at the Bitcoin ETF proposals. 
  • The financial watchdog has set a deadline for final changes. 
  • Reports indicate increasing signs of a potential ETF approval in early January. 

With just a few days remaining until January, excitement for the Bitcoin exchange-traded funds (ETF) has reached unprecedented levels. The US Securities and Exchange Commission (SEC) is taking its rounds with the applicants, ensuring that the i’s are dotted and the t’s are crossed before it potentially approves one of the most revolutionary financial instruments, changing the course of the financial world forever.

The SEC Sets Deadline For Final Changes

According to reports , the SEC is finally warming up to Bitcoin Spot ETF proposals and is expected to make a historic decision by January 10, 2024. This date marks the final decision point for the SEC to either approve or deny the application for the first Spot Bitcoin ETF. 

In preparation for the January decision, officials from the US SEC met with representatives of at least seven applicant companies, including BlackRock, Grayscale Investments, and 21 Shares, hoping to launch Bitcoin spot ETFs. According to close sources , the financial watchdog instructed at least two firms to submit final changes by the end of this business week on December 29. 

 

As per reports , the SEC has told applicants that issuers failing to meet the deadline for final changes will not be part of the first wave of potential spot Bitcoin ETF approvals in early January.

While there are increasing signs of a potential spot ETF approval in early January, it’s important to note that the SEC retains the authority to reject proposals outright on the deadline. So far, the regulatory body has been delaying its decision, keeping the market in suspense regarding whether it will reject or approve the proposal.

On the Flipside

  • One critical aspect of the SEC’s potential approval of the ETF is its stern request that investments in these assets be made by using cash only . 
  • The SEC’s cautious approach to crypto spot EFTs means that the regulator does not see crypto assets as equal to traditional ones. 

Why This Matters

The SEC’s upcoming decision to approve the first spot Bitcoin ETF could redefine the dynamics between traditional finance and the burgeoning digital asset sector, allowing the latter to break into the mainstream.

 
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23

Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market

Eli Lilly is collaborating with Hims & Hers Health, leveraging the telehealth company’s large customer base to expand access to its blockbuster weight loss drugs and boost sales of medications, including its new oral weight loss drug Foundayo.

智通财经•2026/11/06 12:37
Eli Lilly (LLY.US) "lowers its stance" and joins forces with former rival Hims (HIMS.US) to compete for the self-pay weight loss drug market